CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a research note issued to investors on Monday. The brokerage issued a sell rating on the stock.

CEL-SCI Trading Up 15.0 %

Shares of CEL-SCI stock opened at $0.51 on Monday. The company has a market capitalization of $38.00 million, a price-to-earnings ratio of -1.07 and a beta of 0.69. The company has a quick ratio of 1.09, a current ratio of 1.31 and a debt-to-equity ratio of 0.62. CEL-SCI has a 12-month low of $0.33 and a 12-month high of $2.50. The firm’s 50-day moving average price is $0.48 and its two-hundred day moving average price is $0.78.

Hedge Funds Weigh In On CEL-SCI

Hedge funds and other institutional investors have recently modified their holdings of the business. Thoroughbred Financial Services LLC boosted its stake in CEL-SCI by 40.1% in the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock valued at $76,000 after buying an additional 54,900 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of CEL-SCI by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after purchasing an additional 53,879 shares in the last quarter. Plotkin Financial Advisors LLC bought a new stake in shares of CEL-SCI during the 3rd quarter valued at approximately $98,000. Finally, Calton & Associates Inc. acquired a new position in CEL-SCI during the 3rd quarter worth approximately $50,000. Institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.